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     This study is based on 29 patients undergoing resection for pulmonary metastases 
from 1960 to 1981 in our clinics. 
     Factors concerning their prognosis are discussed in this study. 
1) Prognosis following surgery is associated with the origin of the primary disease, the 
   sizes and numbers of pulmonary metastases, and the disease-free period. 
2) Pulmonary metastases arising from original tumors with slow growth rate, such as 
   thyroid cancer, breast cancer, and some of osteogenic sarcomas, are favorable candi-
   dates for surgical treatment. 
3) Operative methods of choice are not essential in anticipating better results. Complete 
   removal of the tumor is required. We assume that improved chemotherapy may be 
   contributary to a gain in a longer survival.
                  INTRODUCTION 
     Surgical indication for metastatic lung tumors has become recognized and accepted 
in improving survival. 
     A gain of long-term survivor following pulmonary resection appeared encouraging 
surgeons. It, however, is clear that metastasis in the lung means the tumor is spreading 
elsewhere in the body and so satisfactory results are not necessarily ensured by surgical 
treatment for pulmonary metastases. In this study, influential factors on prognosis follow-
ing lung resection for the treatments of pulmonary metastases are evaluated on the basis 
of the results of our clinical experience with 29 cases treated surgically.
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MATERIAL AND METHOD
     A total of 29 cases were eligible 
for evaluation in this study, 22 were in 
cancer origin and the remaining 7 were 
in sarcoma origin (Table 1). Primary 
cancer lesions consisted of chorionepithe-
lioma in 5, breast cancer in 4, lung cancer 
in 4, gastric cancer in 3, thyroid cancer, 
renal cancer, rectal cancer, hepatic can-
cer, cancer of the cervix and cancer of 
salivary gland in 1 respectively. 
      The primary sarcoma lesions were 
osteogenic in 4, and synovial sarcoma , re-
ticulumcell sarcoma and malignant his-
tiocytoma in 1 respectively. The surgical 
specimens were histologically examined 
and the histologic types of metastatic 
lesions in the lung were proved to be 
similar to those of the original lesions.
    Table 1 Patients and primary disease 
 Primary tumor No of Primary tumor No of 
Cancer cases Sarcoma cases 
chorion- osteogenic 
 epithelioma 5 sarcoma 4 
breast cancer 4 synovial sarcoma 1 
lung cancer 4 reticulum 1                        c
ell sarcoma 
gastric cancer 3 malignant 1                      histiocytoma 
thyroid cancer 1 
renal cancer 1 
rectal cancer 1 
hepatic cancer 1 
cervix cancer 1 
salivary gland 1 
  cancer 
    total 22 I 7
     The tumor doubling times were retrospectively assessed with measurement of the 
sizes of tumorous shadows in serial chest XP films .
RESULTS
     According to age distribution, patients with sarcoma were younger than those with 
cancer. 
     Their ages ranged from 10 to 68 (Table 2). 
     The locations of metastatic tumors in the lungs were the right upper lobe in 6, 
right middle lobe in 3, right lower lobe in 11, left upper lobe in 4 and left lower lobe 
in 5. 
     Solitary metastatic tumors in the lungs were seen in 22 (75.9%) and multiples 
in 7 (24.1%). The numbers of tumors in the preoperative evaluation based on findings 
on chest XP films, were not in concordance with those at surgery in two cases. The 
additional metastatic lesions were detected. 
     The sizes of the metastatic tumors in the lungs ranged from less than 1 cm to 6.5 
cm as shown in Table 3. The sizes of cancer at operation were not different from those 
of sarcoma. Time intervals from the first operation to the appearance of metastatic tumor 
shadow on chest XP films varied from the same time with the first operation to 6.8 years 
(Table 4). It, however, was relatively short for sarcoma. Most of them were within 1 
year. The surgical procedures of choice were wedge resection in 9, segmentectomy in
    Table 2 Age and sex of patients 
                              sex
Age (years) Male Femal 
 -20 1(1) 1(1) 
 ^-30 2(2) 0 
 -V40 1(1) 2 
  ^-50 2 3 
 -60 3 10(2) 
  60 2 2 
            ( ) sarcoma
   Table 4 The time interval from the 
           first operation to detected
            pulmonary metastases
      Disease-free No of 
     interval (years) cases 
the same with the time 2 
o f primary tumor detected 
     whthin 1 8(5) 
           2 4
          3 8(1) 
           5 2
      over 5 5(1) 
            ( ) sarcoma
Table 3 Tumor size 
Size of metastatic No of 
tumor (cm) cases (%) 
      1.0 3 (10.3) 
     2.0 10(4) (34.5) 
      3.0 3 (10.3) 
     4.0 4(2) (13.8) 
      5.0 3 (10.3) 
    5.1 6(1) (20.7) 
          ( ) sarcoma
 Table 5 The operative methods 
        employed in patients with 
         pulmonary metastases 
Operative method No of                                cases 
 wedge resection 9 
 segmentectomy 3 
 lobectomy 18 
 bi-lobectomy 2
3, lobectomy in 18 and bilobectomy in 2 (Table 5). 
      Lobectomy was more preferable in our institute. 
      Lymph node dissection was performed in 14. Nine of the 14 cases had no lymph 
node involvement, and 2 had involved lymph nodes in the hilum of the lung and 3 in 
the mediastinum. 
      Prognosis was analyzed according to original diseases, the elapsed time between 
the first and second operations and the sizes of metastatic tumors. Survivors of more 
than 5 years were among patients with breast cancer, thyroid cancer and cancer of the 
salivary gland. In comparision, the survival rate of sarcoma except for some of the 
osteogenic sarcomas did not exceed over 2 years. 
      As for the period of time between the first and second surgery (Fig. 1), the 
survival period following the second surgery is well correlated with the prolonged disease-
free time interval. The longer the tumor doubling time, the better the assurance of 
survival. (Fig. 2), but a long doubling time of over 40 days did not permit a satisfactory 
prognosis. 
      The tumor sizes of pulmonary metastases were inversely proportional to survival 
time (Fig. 3). The tumor size of less than 2cm in diameter had led to a considerably 
fair prognosis. 
      The operative procedure with regard to lymph node dissection was not helpful to
obtain a better survival. 
     The degrees of involved lymph nodes were closely associated with survival follo-
wing surgery (Fig. 4). 
     The overall survival rates in surgical treatments of pulmonary metastases were 
encouraging as shown in Fig. 5.
Fig I Relationship between prognosis and 
       disease-free interval
Fig 2 Relationship between prognosis and 
      tumor doubling time
Fig 3 Ralationship between prognosis and 
       tumor size
Fig 4 Relationship between prognosis and 
      lymph node involvement or lymph
      node dissection
Fig 5 Survival rate in the surgical treatment 
       of pulmonary metastases
Fig 6 The difference of survival rate in 
      solitary and multiple lesions
     The survival times in solitray lesions were excellent as compared with those in mul -
tiple lesions (Fig. 6). There were no significant differences in prognoses between after 
performing lobectomy and segmentectomy. All patients received various anticancer drugs 
in the postoperative period. Long-term surviors of more than 3 years following the second 
surgery were given a protracted anticancer drug regimen of more than 2 years after the 
second operation. 
                    DISCUSSION 
     Surgery in the treatment of pulmonary metastases is now acceptable in patients 
with solitary lesion limited to the lung. i>-3> 
     Surgical treatment of pulmonary metastases was indicated as reported by Thom-
ford.4) 
     The primary site must be controlled ; There must be no extrapulmonary metastasis ; 
The patient must be a good condition for operative risk and the metastatic site must be 
solitary, not multiple. 
     In this study, the prognosis following surgery for the treatment of pulmonary 
metastases are closely related to a longer tumor-doubling time, a long disease-free time 
interval and a smaller-sized lesion or tumor. From the perspective of kinds of original 
diseases types, there were gratifying results in breast cancer, thyroid cancer, cancer of 
the salivary gland, osteogenic sarcoma and synovial sarcoma, all which responded well 
to and were well controlled by chemotherapy. With the development of improved chemo-
therapy, it appear possible to suppress postoperative recurrences to some extent as well 
as to minimize the appearance of pulmonary metastases. 
     Surgical results have improved, particulary in breast cancer, colon cancer and 
osteogenic sarcoma.
     The schedule of treatment for pulmonary metastases should be established using 
improved chemotherapy in combination with irradiation and immunotherapy. If metastatic 
tumor, however, increases in size, surgery is mandatory. 
     It is obvious that surgical treatment is effective in those whose lung tumor sizes 
are smaller, disease-free time intervals are longer, the original lesions are well controlled 
and metastatic tumors are solitary. 
     Whether the prognosis following surgery is fair or poor remains in doubt. Post-
operative anticancer regimens are necessary for preventing occurence or recurrence and 
providing prolongation of survival time .1)6) 
     As a result of this study, we conclude that surgical operative methods including 
lymph node dissection are not responsible for prolonged survival. Limited resection as 
elective surgical procedure in the treatment of pulmonary metastases is beneficial in 
preserving sufficient functioning pulmonary tissue. We believe that the benefit from the 
limited resection performed seems to outweigh the risk of remaining unresected micro-
metastatic foci. 
     The result of lobectomy performed in the surgical treatment of metastatic tumor is 
not superior to that of limited resection although available data must be accumulated. 
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